Clinical Trials
59 trialsMAPtivate-6
Pfizer
CPIT001
Hackensack Meridian Health
CMP-001 for Relapsed and Refractory Lymphoma
University of Iowa
HeartPhone Cancer Survivors Trial 2019
Penn State University
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
Otsuka Pharmaceutical Co., Ltd.
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
CRISPR Therapeutics
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
A Study of Isatuximab-based Therapy in Participants With Lymphoma
Sanofi
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Pfizer
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
CytomX Therapeutics
Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL
Gamida Cell ltd
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
Oncternal Therapeutics, Inc
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
Takeda
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Columbia University
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
Celgene
ACY-1215 for Relapsed/Refractory Lymphoid Malignancies
Columbia University
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
ModernaTX, Inc.
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
IGM Biosciences, Inc.
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
Altor BioScience
Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients
Bayer
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
City of Hope Medical Center
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Asana BioSciences
PIVOT IO 020
Bristol-Myers Squibb
Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Case Comprehensive Cancer Center
High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT
Universitätsklinikum Hamburg-Eppendorf
MT-3724NHL001
Molecular Templates, Inc.
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
Yale University
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
Swiss Cancer Institute
Study of INCB053914 in Subjects With Advanced Malignancies
Incyte Corporation
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
National Institutes of Health Clinical Center (CC)
Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL
Alopexx Oncology, LLC
DI-Leu16-IL2
Alopexx Oncology, LLC
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
Effector Therapeutics
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Therapeutic Advances in Childhood Leukemia Consortium
Phase II Study of TAK228 in Relapsed Lymphoma
M.D. Anderson Cancer Center
Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers
Mirror Biologics, Inc.
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
M.D. Anderson Cancer Center
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
OHSU Knight Cancer Institute
VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas
Celgene
Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
Northwestern University
A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma
AHS Cancer Control Alberta
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
M.D. Anderson Cancer Center
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Incyte Corporation
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
Northwestern University
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
Columbia University
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Milton S. Hershey Medical Center
Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
R²-DHAP
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer
Masonic Cancer Center, University of Minnesota